Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 154 No. 7 (2024)

Intravenous ferric carboxymaltose is associated with lowering of plasma phosphate levels in patients with gastric bypass surgery: a retrospective case series

  • Cindy Pereira Portela
  • Lucie Favre
  • Isabella Locatelli
  • Olivier Bonny
DOI
https://doi.org/10.57187/s.3771
Cite this as:
Swiss Med Wkly. 2024;154:3771
Published
24.07.2024

Summary

AIMS: Bariatric surgery induces several micronutrient deficiencies that require supplementation. For iron, parenteral infusions are usually preferred over oral supplementation. Ferric carboxymaltose infusion has been associated with hypophosphataemia, mostly transient and asymptomatic. However, in some cases, ferric carboxymaltose-induced hypophosphataemia may persist for weeks to months and may induce muscle weakness, osteomalacia and bone fractures. The aim of this study was to identify possible predictors of a clinically relevant decrease in serum phosphate after ferric carboxymaltose infusion in patients with previous Roux-en-Y gastric bypass.

METHODS: Patients with previous Roux-en-Y gastric bypass who received ferric carboxymaltose infusions between January 2018 and September 2019 and had recorded phosphataemia before and after ferric carboxymaltose infusion at the Lausanne University Hospital, Lausanne, Switzerland, were studied retrospectively. A multiple linear regression model was built with delta phosphataemia as the outcome to investigate the factors related to magnitude of serum phosphate lowering.

RESULTS: Seventy-seven patients (70 females and 7 males) with previous Roux-en-Y gastric bypass were studied. Mean age (SD) was 43.2 (10.7) years and median BMI was 30.9 kg/m2 (IQR 27.9–36.4). Sixty-eight patients (88.3%) received an infusion of 500 mg ferric carboxymaltose and 9 patients (11.7%) received 250 mg ferric carboxymaltose. Forty-nine patients (63.6%) developed hypophosphataemia (<0.8 mmol/l) after ferric carboxymaltose infusion. Median plasma phosphate significantly decreased by 0.33 mmol/l (IQR 0.14–0.49) (p<0.0001). Multiple linear regression identified the ferric carboxymaltose dose as the only risk factor significantly associated with the magnitude of serum phosphate lowering, with an additional mean loss of 0.26 mmol/l with a 500 mg infusion compared to a 250 mg infusion (p = 0.020).

CONCLUSION: Ferric carboxymaltose infusions substantially decreased plasma phosphate levels in patients with previous Roux-en-Y gastric bypass. Compared to a dose of 250 mg, infusion of a dose of 500 mg ferric carboxymaltose decreased the plasma phosphate further in this population.

References

  1. Enani G, Bilgic E, Lebedeva E, Delisle M, Vergis A, Hardy K. The incidence of iron deficiency anemia post-Roux-en-Y gastric bypass and sleeve gastrectomy: a systematic review. Surg Endosc. 2020 Jul;34(7):3002–10. 10.1007/s00464-019-07092-3 DOI: https://doi.org/10.1007/s00464-019-07092-3
  2. Engebretsen KV, Blom-Høgestøl IK, Hewitt S, Risstad H, Moum B, Kristinsson JA, et al. Anemia following Roux-en-Y gastric bypass for morbid obesity; a 5-year follow-up study. Scand J Gastroenterol. 2018 Aug;53(8):917–22. 10.1080/00365521.2018.1489892 DOI: https://doi.org/10.1080/00365521.2018.1489892
  3. Rognoni C, Venturini S, Meregaglia M, Marmifero M, Tarricone R. Efficacy and Safety of Ferric Carboxymaltose and Other Formulations in Iron-Deficient Patients: A Systematic Review and Network Meta-analysis of Randomised Controlled Trials. Clin Drug Investig. 2016 Mar;36(3):177–94. 10.1007/s40261-015-0361-z DOI: https://doi.org/10.1007/s40261-015-0361-z
  4. Schaefer B, Meindl E, Wagner S, Tilg H, Zoller H. Intravenous iron supplementation therapy. Mol Aspects Med. 2020 Oct;75:100862. 10.1016/j.mam.2020.100862 DOI: https://doi.org/10.1016/j.mam.2020.100862
  5. Blumenstein I, Shanbhag S, Langguth P, Kalra PA, Zoller H, Lim W. Newer formulations of intravenous iron: a review of their chemistry and key safety aspects - hypersensitivity, hypophosphatemia, and cardiovascular safety. Expert Opin Drug Saf. 2021;20(7):757-69. Epub 20210515. doi: 10.1080/14740338.2021.1912010. PubMed PMID: 33993818. DOI: https://doi.org/10.1080/14740338.2021.1912010
  6. Schaefer B, Tobiasch M, Viveiros A, Tilg H, Kennedy NA, Wolf M, et al. Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis. Br J Clin Pharmacol. 2021;87(5):2256-73. Epub 20201207. doi: 10.1111/bcp.14643. PubMed PMID: 33188534; PubMed Central PMCID: PMC8247006. DOI: https://doi.org/10.1111/bcp.14643
  7. Wolf M, Chertow GM, Macdougall IC, Kaper R, Krop J, Strauss W. Randomized trial of intravenous iron-induced hypophosphatemia. JCI Insight. 2018 Dec;3(23):e124486. 10.1172/jci.insight.124486 DOI: https://doi.org/10.1172/jci.insight.124486
  8. Rosano G, Schiefke I, Göhring UM, Fabien V, Bonassi S, Stein J. A Pooled Analysis of Serum Phosphate Measurements and Potential Hypophosphataemia Events in 45 Interventional Trials with Ferric Carboxymaltose. J Clin Med. 2020;9(11). Epub 20201106. doi: 10.3390/jcm9113587. PubMed PMID: 33172157; PubMed Central PMCID: PMC7694774. DOI: https://doi.org/10.3390/jcm9113587
  9. Zoller H, Schaefer B, Glodny B. Iron-induced hypophosphatemia: an emerging complication. Curr Opin Nephrol Hypertens. 2017 Jul;26(4):266–75. 10.1097/MNH.0000000000000329 DOI: https://doi.org/10.1097/MNH.0000000000000329
  10. Glaspy JA, Wolf M, Strauss WE. Intravenous Iron-Induced Hypophosphatemia: An Emerging Syndrome. Adv Ther. 2021;38(7):3531-49. Epub 20210530. doi: 10.1007/s12325-021-01770-2. PubMed PMID: 34053011; PubMed Central PMCID: PMC8279965.
  11. Wolf M, Rubin J, Achebe M, Econs MJ, Peacock M, Imel EA, et al. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials. JAMA. 2020 Feb;323(5):432–43. 10.1001/jama.2019.22450 DOI: https://doi.org/10.1001/jama.2019.22450
  12. Favrat B, Balck K, Breymann C, Hedenus M, Keller T, Mezzacasa A, et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women—PREFER a randomized, placebo-controlled study. PLoS One. 2014 Apr;9(4):e94217. 10.1371/journal.pone.0094217 DOI: https://doi.org/10.1371/journal.pone.0094217
  13. Schoeb M, Räss A, Frei N, Aczél S, Brändle M, Bilz S. High Risk of Hypophosphatemia in Patients with Previous Bariatric Surgery Receiving Ferric Carboxymaltose: A Prospective Cohort Study. Obes Surg. 2020 Jul;30(7):2659–66. 10.1007/s11695-020-04544-x DOI: https://doi.org/10.1007/s11695-020-04544-x
  14. Kassianides X, Bhandari S. Hypophosphataemia, fibroblast growth factor 23 and third-generation intravenous iron compounds: a narrative review. Drugs Context. 2021;10. Epub 20210119. doi: 10.7573/dic.2020-11-3. PubMed PMID: 33519940; PubMed Central PMCID: PMC7819638. DOI: https://doi.org/10.7573/dic.2020-11-3
  15. Bager P, Hvas CL, Dahlerup JF. Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions. Br J Clin Pharmacol. 2017;83(5):1118-25. Epub 20170118. doi: 10.1111/bcp.13189. PubMed PMID: 27859495; PubMed Central PMCID: PMC5401972. DOI: https://doi.org/10.1111/bcp.13189
  16. Coppolino G, Nicotera R, Cernaro V, Calimeri S, Leonardi G, Cosentino S, et al. Iron Infusion and Induced Hypophosphatemia: The Role of Fibroblast Growth Factor-23. Ther Apher Dial. 2020;24(3):258-64. Epub 20191025. doi: 10.1111/1744-9987.13435. PubMed PMID: 31483921. DOI: https://doi.org/10.1111/1744-9987.13435
  17. Hardy S, Vandemergel X. Intravenous iron administration and hypophosphatemia in clinical practice. Int J Rheumatol. 2015;2015:468675. 10.1155/2015/468675 DOI: https://doi.org/10.1155/2015/468675
  18. Schaefer B, Würtinger P, Finkenstedt A, Braithwaite V, Viveiros A, Effenberger M, et al. Choice of High-Dose Intravenous Iron Preparation Determines Hypophosphatemia Risk. PLoS One. 2016 Dec;11(12):e0167146. 10.1371/journal.pone.0167146 DOI: https://doi.org/10.1371/journal.pone.0167146
  19. Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res. 2013 Aug;28(8):1793–803. 10.1002/jbmr.1923 DOI: https://doi.org/10.1002/jbmr.1923
  20. Schaefer B, Tobiasch M, Wagner S, Glodny B, Tilg H, Wolf M, et al. Hypophosphatemia after intravenous iron therapy: Comprehensive review of clinical findings and recommendations for management. Bone. 2021;154:116202. Epub 20210915. doi: 10.1016/j.bone.2021.116202. PubMed PMID: 34534708. DOI: https://doi.org/10.1016/j.bone.2021.116202
  21. SMOB. Directives pour le traitement chirurgical de l’obésité. 2021.
  22. Jepsen P, Tapper EB, Deleuran T, Kazankov K, Askgaard G, Sorensen HT, et al. Risk and Outcome of Venous and Arterial Thrombosis in Patients With Cirrhosis: A Danish Nation-wide Cohort Study. Hepatology. 2021;74(5):2725-34. Epub 20210909. doi: 10.1002/hep.32019. PubMed PMID: 34137045; PubMed Central PMCID: PMC8542589. DOI: https://doi.org/10.1002/hep.32019
  23. Young MT, Phelan MJ, Nguyen NT. A Decade Analysis of Trends and Outcomes of Male vs Female Patients Who Underwent Bariatric Surgery. J Am Coll Surg. 2016;222(3):226-31. Epub 20151217. doi: 10.1016/j.jamcollsurg.2015.11.033. PubMed PMID: 26782151. DOI: https://doi.org/10.1016/j.jamcollsurg.2015.11.033
  24. Callejas-Moraga EL, Casado E, Gomez-Nuñez M, Caresia-Aroztegui AP. Severe osteomalacia with multiple insufficiency fractures secondary to intravenous iron therapy in a patient with Rendu-Osler-Weber syndrome. Bone Rep. 2020 Aug;13:100712. 10.1016/j.bonr.2020.100712 DOI: https://doi.org/10.1016/j.bonr.2020.100712
  25. Sangrós Sahún MJ, Goñi Gironés E, Camarero Salazar A, Estébanez Estébanez C, Lozano Martínez ME. Symptomatic hypophosphataemic osteomalacia secondary to the treatment with iron carboxymaltose detected in bone scintigraphy. Rev Esp Med Nucl Imagen Mol. 2016;35(6):391–3. 10.1016/j.remn.2016.04.006 10.1016/j.remnie.2016.09.002 DOI: https://doi.org/10.1016/j.remnie.2016.09.002
  26. Moore KL, Kildahl-Andersen O, Kildahl-Andersen R, Tjønnfjord GE. Uncommon adverse effect of a common medication. Tidsskr Nor Laegeforen. 2013 Jan;133(2):165. 10.4045/tidsskr.12.0494 DOI: https://doi.org/10.4045/tidsskr.12.0494
  27. Bartko J, Roschger P, Zandieh S, Brehm A, Zwerina J, Klaushofer K. Hypophosphatemia, Severe Bone Pain, Gait Disturbance, and Fatigue Fractures After Iron Substitution in Inflammatory Bowel Disease: A Case Report. J Bone Miner Res. 2018 Mar;33(3):534–9. 10.1002/jbmr.3319 DOI: https://doi.org/10.1002/jbmr.3319
  28. Klein K, Asaad S, Econs M, Rubin JE. Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration. BMJ Case Rep. 2018 Jan;2018:bcr2017222851. 10.1136/bcr-2017-222851 DOI: https://doi.org/10.1136/bcr-2017-222851
  29. Schaefer B, Glodny B, Zoller H. Blood and Bone Loser. Gastroenterology. 2017 May;152(6):e5–6. 10.1053/j.gastro.2016.09.050 DOI: https://doi.org/10.1053/j.gastro.2016.09.050
  30. Fierz YC, Kenmeni R, Gonthier A, Lier F, Pralong F, Coti Bertrand P. Severe and prolonged hypophosphatemia after intravenous iron administration in a malnourished patient. Eur J Clin Nutr. 2014 Apr;68(4):531–3. 10.1038/ejcn.2014.20 DOI: https://doi.org/10.1038/ejcn.2014.20
  31. Axelsson KF, Werling M, Eliasson B, Szabo E, Näslund I, Wedel H, et al. Fracture Risk After Gastric Bypass Surgery: A Retrospective Cohort Study. J Bone Miner Res. 2018 Dec;33(12):2122–31. 10.1002/jbmr.3553 DOI: https://doi.org/10.1002/jbmr.3553
  32. Yu EW, Kim SC, Sturgeon DJ, Lindeman KG, Weissman JS. Fracture Risk After Roux-en-Y Gastric Bypass vs Adjustable Gastric Banding Among Medicare Beneficiaries. JAMA Surg. 2019 Aug;154(8):746–53. 10.1001/jamasurg.2019.1157 DOI: https://doi.org/10.1001/jamasurg.2019.1157
  33. Fashandi AZ, Mehaffey JH, Hawkins RB, Schirmer B, Hallowell PT. Bariatric surgery increases risk of bone fracture. Surg Endosc. 2018 Jun;32(6):2650–5. 10.1007/s00464-017-5628-4 DOI: https://doi.org/10.1007/s00464-017-5628-4
  34. Summary of Recommendation Statements. Kidney Int Suppl (2011). 2013;3(3):263-5. doi: 10.1038/kisup.2013.31. PubMed PMID: 25018998; PubMed Central PMCID: PMC4089618. DOI: https://doi.org/10.1038/kisup.2013.31

Most read articles by the same author(s)